We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Metagenomi Inc (MGX) USD0.0001

Sell:$1.81 Buy:$1.82 Change: $0.16 (9.70%)
NASDAQ:0.03%
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:$1.81
Buy:$1.82
Change: $0.16 (9.70%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:$1.81
Buy:$1.82
Change: $0.16 (9.70%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed an expansive and modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. Its platform enables it to rapidly and effectively find, screen, and select tools with the highest targetability, specificity, and efficiency in order to develop them into genetic medicine.

Contact details

Address:
5959 Horton St, Floor 7
EMERYVILLE
94608
United States
Telephone:
+1 (510) 8714880
Website:
https://metagenomi.co/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MGX
ISIN:
US59102M1045
Market cap:
$61.75 million
Shares in issue:
37.42 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Juergen Eckhardt
    Chairman of the Board
  • Jian Irish
    President, Chief Operating Officer
  • Brian Thomas
    Chief Executive Officer, Founder, Director
  • Jak Knowles
    Co-Founder
  • Pamela Wapnick
    Chief Financial Officer
  • Simon Harnest
    Senior Vice President - Strategy, Chief Investment Officer
  • Luis Borges
    Chief Scientific Officer
  • Mike Conway
    Vice President - Finance
  • Simren Delaney
    Vice President - Legal
  • Sarah Noonberg
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.